» Articles » PMID: 25526031

Multiple Myeloma Cells Recruit Tumor-supportive Macrophages Through the CXCR4/CXCL12 Axis and Promote Their Polarization Toward the M2 Phenotype

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Dec 20
PMID 25526031
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) cells specifically attract peripheral-blood monocytes, while interaction of MM with bone marrow stromal cells (BMSCs) significantly increased monocyte recruitment (p<0.01). The CXCL12 chemokine, produced by both the MM and BMSCs, was found to be a critical regulator of monocyte migration. CXCL12 production was up-regulated under MM-BMSCs co-culture conditions, whereas blockage with anti-CXCR4 antibodies significantly abrogated monocyte recruitment toward a MM-derived conditioned medium (p<0.01). Furthermore, elevated levels of CXCL12 were detected in MM, but not in normal BM samples, whereas malignant MM cells often represented the source of increased CXCL12 in the BM. Blood-derived macrophages effectively supported MM cells proliferation and protected them from chemotherapy-induced apoptosis. Importantly, MM cells affected macrophage polarization, elevating the expression of M2-related scavenger receptor CD206 in macrophages and blocking LPS-induced TNFα secretion (a hallmark of M1 response). Of note, MM-educated macrophages suppressed T-cell proliferation and IFNγ production in response to activation. Finally, increased numbers of CXCR4-expressing CD163+CD206+ macrophages were detected in the BM of MM patients (n=25) in comparison to MGUS (n=11) and normal specimens (n=8). Taken together, these results identify macrophages as important players in MM tumorogenicity, and recognize the CXCR4/CXCL12 axis as a critical regulator of MM-stroma interactions and microenvironment formation.

Citing Articles

A comprehensive analysis of molecular characteristics of hot and cold tumor of gastric cancer.

Lv C, Chen T, Li J, Shan Y, Zhou H Cancer Immunol Immunother. 2025; 74(3):102.

PMID: 39904894 PMC: 11794920. DOI: 10.1007/s00262-025-03954-z.


New horizons in our understanding of precursor multiple myeloma and early interception.

Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.

PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.


Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders.

Daccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C J Allergy Clin Immunol. 2024; 154(5):1216-1231.

PMID: 39098508 PMC: 11560686. DOI: 10.1016/j.jaci.2024.07.021.


Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.

Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L Front Oncol. 2024; 14:1413494.

PMID: 39087026 PMC: 11288838. DOI: 10.3389/fonc.2024.1413494.


Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.

Li Z, Duan D, Li L, Peng D, Ming Y, Ni R Front Pharmacol. 2024; 15:1382256.

PMID: 38957393 PMC: 11217528. DOI: 10.3389/fphar.2024.1382256.


References
1.
Podar K, Chauhan D, Anderson K . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2008; 23(1):10-24. PMC: 3418600. DOI: 10.1038/leu.2008.259. View

2.
Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E . Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 2013; 19(13):3495-507. DOI: 10.1158/1078-0432.CCR-12-3015. View

3.
Peng K, Dogan A, Vrana J, Liu C, Ong H, Kumar S . Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol. 2009; 84(7):401-7. PMC: 2805200. DOI: 10.1002/ajh.21444. View

4.
Azab A, Azab F, Blotta S, Pitsillides C, Thompson B, Runnels J . RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009; 114(3):619-29. PMC: 2713475. DOI: 10.1182/blood-2009-01-199281. View

5.
Raab M, Podar K, Breitkreutz I, Richardson P, Anderson K . Multiple myeloma. Lancet. 2009; 374(9686):324-39. DOI: 10.1016/S0140-6736(09)60221-X. View